Fetal fraction of cell free DNA in screening for hypertensive disorders at 11–13 weeks

References

• Lo YM, Leung TN, Tein MS, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem. 1999;45(2):184–188.
   PubMed Web of Science ®Google Scholar
• Smid M, Vassallo A, Lagona F, et al. Quantitative analysis of fetal DNA in maternal plasma in pathological conditions associated with placental abnormalities. Ann NY Acad Sci. 2001;945:132–137.
   PubMed Web of Science ®Google Scholar
• Zhong XY, Laivuori H, Livingston JC, et al. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am J Obstet Gynecol. 2001;184(3):414–419.
   PubMed Web of Science ®Google Scholar
• Farina A, Sekizawa A, Rizzo N, et al. Cell free fetal DNA (SRY locus) concentration in maternal plasma is directly correlated to the time elapsed from the onset of preeclampsia to the collection of blood. Prenat Diagn. 2004;24(4):293–297.
   PubMed Web of Science ®Google Scholar
• Alberry MS, Maddocks DG, Hadi MA, et al. Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. Am J Obstet Gynecol. 2009;200:98 e1–6.
   PubMed Web of Science ®Google Scholar
• Lau TW, Leung TN, Chan LY, et al. Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clin Chem. 2002;48(12):2141–2146.
   PubMed Web of Science ®Google Scholar
• Kim SY, Kim HJ, Park SY, et al. Early prediction of hypertensive disorders of pregnancy using cell-free fetal DNA, cell-free total DNA, and biochemical markers. Fetal Diagn Ther. 2016;40(4):255–262.
   PubMed Web of Science ®Google Scholar
• Sifakis S, Zaravinos A, Maiz N, et al. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol. 2009;201(5):472.e1–472.e7.
   PubMed Web of Science ®Google Scholar
• Rolnik DL, O’Gorman N, Fiolna M, et al. Maternal plasma cell-free DNA in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2015;45(1):106–111.
   PubMed Web of Science ®Google Scholar
• Krishna I, Badell M, Loucks TL, et al. Adverse perinatal outcomes are more frequent in pregnancies with a low fetal fraction result on noninvasive prenatal testing. Prenat Diagn. 2016;36(3):210–215.
   PubMed Web of Science ®Google Scholar
• Suzumori N, Sekizawa A, Ebara T, et al. Fetal cell-free DNA fraction in maternal plasma for the prediction of hypertensive disorders of pregnancy. Eur J Obstet Gynecol Reprod Biol. 2018;224:165–169.
   PubMed Web of Science ®Google Scholar
• Bender WR, Koelper NC, Sammel MD, et al. Association of fetal fraction of cell-free DNA and hypertensive disorders of pregnancy. Amer J Perinatol. 2019;36(03):311–316.
   PubMedGoogle Scholar
• Gerson KD, Truong S, Haviland MJ, et al. Low fetal fraction of cell-free DNA predicts placental dysfunction and hypertensive disease in pregnancy. Pregnancy Hypertens. 2019;16:148–153.
   PubMed Web of Science ®Google Scholar
• Poon LC, Musci T, Song K, et al. Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks’ gestation: relation to fetal and maternal characteristics and pregnancy outcomes. Fetal Diagn Ther. 2013;33(4):215–223.
   PubMed Web of Science ®Google Scholar
• Rolnik DL, da Silva Costa F, Lee TJ, et al. Association between fetal fraction on cell-free DNA testing and first-trimester markers for pre-eclampsia. Ultrasound Obstet Gynecol. 2018;52(6):722–727.
   PubMed Web of Science ®Google Scholar
• O’Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. Am J Obstet Gynecol. 2016;214(1):103.e1–103.e12.
   PubMed Web of Science ®Google Scholar
• Kagan KO, Wright D, Baker A, et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 2008;31(6):618–624.
   PubMed Web of Science ®Google Scholar
• Syngelaki A, Hammami A, Bower S, et al. Diagnosis of fetal non-chromosomal abnormalities on routine ultrasound examination at 11–13 weeks’ gestation. Ultrasound Obstet Gynecol. 2019;54(4):468–476.
   PubMed Web of Science ®Google Scholar
• Plasencia W, Maiz N, Bonino S, et al. Uterine artery Doppler at 11+0 to 13+6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;30(5):742–749.
   PubMed Web of Science ®Google Scholar
• Poon LC, Zymeri NA, Zamprakou A, et al. Protocol for measurement of mean arterial pressure at 11–13 weeks’ gestation. Fetal Diagn Ther. 2012;31(1):42–48.
   PubMed Web of Science ®Google Scholar
• Sparks AB, Struble CA, Wang ET, et al. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012;206(4):319.e1–319.e9.
   PubMed Web of Science ®Google Scholar
• Schmid M, White K, Stokowski R, et al. Accuracy and reproducibility of fetal-fraction measurement using relative quantitation at polymorphic loci with microarray. Ultrasound Obstet Gynecol. 2018;51(6):813–817.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 202. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2019;133:e1–25.
   Web of Science ®Google Scholar
• Tayyar A, Guerra L, Wright A, et al. Uterine artery pulsatility index in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;45(6):689–697.
   PubMed Web of Science ®Google Scholar
• Wright A, Wright D, Ispas CA, et al. Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;45(6):698–706.
   PubMed Web of Science ®Google Scholar
• Wright D, Silva M, Papadopoulos S, et al. Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;46(1):42–50.
   PubMed Web of Science ®Google Scholar
• Shook LL, Clapp MA, Roberts PS, et al. High fetal fraction on first trimester cell-free DNA aneuploidy screening and adverse pregnancy outcomes. Am J Perinatol. 2020;37(01):008–013.
   PubMedGoogle Scholar
• Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622.
   PubMed Web of Science ®Google Scholar